Roquefort Therapeutics plc (ROQ.L) LSE
Currency In GBp
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In GBp
Address
Eccleston Yards
London, SW1W 9NF
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 3290 9339
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
March 22, 2021
| Name | Title | Pay | Year Born |
| Darrin Matthew Disley | Interim MD & Director | 15,500 | 1967 |
| Stephen Paul West | Executive Chairman | 72,063 | 1972 |
Roquefort Therapeutics plc functions as a biotechnology firm, focusing its efforts on the discovery and development of innovative pharmaceutical treatments. The company's primary research objective is to develop therapies that target Midkine, a circulating growth factor protein and pro-inflammatory mediator, for applications in cancer treatment. Established in 2020, Roquefort Therapeutics plc has its main operations based in London, United Kingdom.